protein disulfide isomerase family A member 3 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored PDIA3P2 profile across patient tissues and cancer cell-line models. PDIA3P2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, PDIA3P2 is differentially expressed in 7, with the highest sampling consensus in STAD. Additionally, PDIA3P2 RNA expression shows 14,258 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight OV, STAD, and ACC as cancer lineages where PDIA3P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDIA3P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDIA3P2 survival associations across molecular data types. PDIA3P2 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDIA3P2 RNA expression–survival associations across cancer types. High PDIA3P2 expression shows unfavorable associations in OV, CESC and UVM, but favorable associations in KIRP, READ and SKCM. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for PDIA3P2 RNA expression.
This table summarizes PDIA3P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for PDIA3P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDIA3P2 shows higher tumor expression in STAD, LUSC, KICH, CHOL, UCEC and LIHC. The STAD box plot shows higher PDIA3P2 RNA expression in tumor versus normal tissue (log2 FC = +0.630, t-test p = .004).
This table shows molecular features associated with PDIA3P2 in patient tissues and cancer cell lines. In patient samples, PDIA3P2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
